Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Triple Negative Breast Cancer Clinical Trial

— TEMPLATE  

Official title:

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04913571
• Other study ID #: TEMPLATE
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 27, 2021
• Est. completion date: June 1, 2023

Study information

• Verified date: May 2021
• Source: Fudan University
• Contact: Jian Zhang, MD,PhD
• Phone: +8664175590
• Email: syner2000[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Triple-negative breast cancer (TNBC) lacks effective treatment options due to the absence of traditional therapeutic targets.This study is a multicentre, prospective trial. The primary objective of the trial was to evaluate the objective response rate to tslelizumab combined with eribulin in different subgroups（subgroup A: TMB High, B: PD-L1 positive，C, immunomodulatory (IM)，D，NanoString superiority，E，other types）of relapse or metastasis TNBC after failure of second-line chemotherapy. Therefore, exploring new therapeutic options and identifying subgroups of patients who may benefit from special treatments has been a focal point of research. Doing so, we expect to guide new investigation efforts in this area.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 265
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Participants fulfilling all of the following inclusion criteria are eligible for the

study:

1. Female patients aged 18-75 years (including cutoff value).

2. Eastern Cooperative Oncology Group Performance Status of 0-1.

3. Life expectancy = 12 weeks.

4. Histopathologically confirmed recurrent (unresectable) or metastatic triple-negative breast cancer; ER and PR negative is defined as ER <1% positive, PR <1% positive. HER-2 negative is defined as HER-2 (-) or (1+) by immunohistochemistry, HER-2 (2+) must be tested by FISH with negative result, HER-2 (1+), FISH is optional and negative;

5. At least one extracranial measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.

6. Previously received more than 2 lines of systemic chemotherapy for metastatic breast cancer.(the adjuvant chemotherapy regimen administered after recurrence within 6 months was considered as the first-line chemotherapy regimen)

7. Adequate organ function, i.e. meeting the following criteria. Hb = 90 g/L (no transfusion within 14 days); ANC = 1.5 × 109 /L; PLT = 75 × 109 /L. Liver function: total bilirubin TBIL = 1.5×ULN (upper limit of normal); ALT and AST = 3×ULN. serum Cr = 1.5×ULN. Left ventricular ejection fraction (LVEF) = 50% QTcF(Fridericia correction) = 470 ms

8. Subjects voluntarily joined the study, signed informed consent.

Exclusion Criteria:

• All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation

1. Patients who have undergone systemic, radical brain or meningeal metastasis (radiotherapy or surgery), but have been confirmed to have been stable for at least 4 weeks, and who have stopped systemic hormonal therapy for more than 2 weeks without clinical symptoms can be included. Innovative brain metastasis patients, the number of transition stoves is =1, and the maximum path <1 cm;

2. Anticancer therapy related toxicities have not resolved or downgraded to Grade 1 or less;

3. Previously received any Eribulin and /or anti PD-1,anti PD-L1, CTL-4 treatment.

4. Participants with active or a history of autoimmune diseases that probably will recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, etc.), or with high risk (e.g. organ transplantation requiring immunosuppressive therapy). However, participants with the following diseases are eligible: skin diseases requiring no systemic treatment (such as eczema, skin rash covering less than 10% of the body surface, psoriasis without ophthalmic symptoms, etc.).

5. Need to receive systemic corticosteroids (dose equivalent to > 10 mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study period. Those under the following conditions are eligible: a) Locally external use or inhaled corticosteroids; b) short-term ( 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases.

6. Suffered from idiopathic lung disease, interstitial lung disease, pulmonary fibrosis, acute lung disease, etc., except for local interstitial pneumonia induced by radiotherapy;

7. There are ascites, pleural effusion, pericardial effusion with clinical symptoms at baseline, those who need drainage, or those who have undergone drainage of serous effusion within 4 weeks before the first dose.

8. Received systemic therapy such as chemotherapy, molecular targeted therapy or other clinical trial drugs within 4 weeks before enrollment; other than observational clinical study

9. Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as carcinoma in situ of the cervix or Non-Melanocytic Tumors of the Skin;

10. Has any serious and/or uncontrolled disease.

11. Have a history of allergies to the drug components of this regimen.

12. Patients with active HBV and HCV infection; stable hepatitis B after drug treatment (HBV virus copy number is higher than the upper limit of reference value) and cured hepatitis C patients (HCV virus copy number exceeds the lower limit of detection method) can be included.

13. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, history of organ transplantation.

14. Pregnant or lactating women.

15. Childbearing female who refuse to accept any contraception practice during the treatment period.

16. The investigator determined who was not suitable for the study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Eribulin
Eribulin
• Tislelizumab
Tislelizumab

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR is the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.	Up to approximately 12 weeks
Secondary	Overall Survival (OS)	Time from date of randomization to the date of death from any cause	Up to approximately 30 months
Secondary	Progression-Free Survival (PFS)	PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.	Up to approximately 30 months